Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug
- Mylan, Sigmapharm lose bid to invalidate patent on drug
- Xarelto drug patent expires in 2024: FDA Orange book
This article is for subscribers only.
Bayer AG and Johnson & Johnson won a judge’s ruling that upheld the validity of a patent on the blood-thinning drug Xarelto and will keep Mylan NV from selling a generic, low-cost version until August 2024, when the patent expires.
Mylan NV and Sigmapharm Laboratories LLC failed to prove the patent shouldn’t have been issued, U.S. District Court Judge Lawrence Stengel in Wilmington, Delaware, said. The companies can’t sell their generic versions of the drug until the patent expires, the judge said in a separate order.